Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Cash & Equivalents (2020 - 2026)

Bioventus filings provide 6 years of Cash & Equivalents readings, the most recent being $51.2 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 23.22% to $51.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $51.2 million, a 23.22% increase, with the full-year FY2025 number at $51.2 million, up 23.22% from a year prior.
  • Cash & Equivalents hit $51.2 million in Q4 2025 for Bioventus, up from $42.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $138.1 million in Q3 2021 to a low of $22.8 million in Q1 2025.
  • Median Cash & Equivalents over the past 5 years was $39.0 million (2022), compared with a mean of $50.3 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 80.63% in 2021 and later tumbled 78.85% in 2022.
  • Bioventus' Cash & Equivalents stood at $43.9 million in 2021, then crashed by 31.29% to $30.2 million in 2022, then increased by 22.45% to $37.0 million in 2023, then grew by 12.49% to $41.6 million in 2024, then increased by 23.22% to $51.2 million in 2025.
  • The last three reported values for Cash & Equivalents were $51.2 million (Q4 2025), $42.2 million (Q3 2025), and $32.9 million (Q2 2025) per Business Quant data.